Earnings Call · Q2 FY2022·2022-08-11

Q2 22EPS +20.00%·Rev n/aQ1 22EPS +14.29%·Rev n/aQ4 21EPS +93.33%·Rev n/aQ3 21EPS -63.64%·Rev n/a⚠ consensus missing

Definium Therapeutics, Inc. DFTX

Robert Barrow — Chief Executive Officer

Schond Greenway — Chief Financial Officer

+11.7%1d on move date+10.0% vs SPY3d+4.6%5d+56.9%

Research tier

Behavioral profile computed for 2 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more DFTX calls or request research access.

More DFTX calls Browse calls Request research access